全文获取类型
收费全文 | 2872719篇 |
免费 | 237171篇 |
国内免费 | 5460篇 |
专业分类
耳鼻咽喉 | 42697篇 |
儿科学 | 88146篇 |
妇产科学 | 78392篇 |
基础医学 | 405778篇 |
口腔科学 | 84042篇 |
临床医学 | 260639篇 |
内科学 | 555938篇 |
皮肤病学 | 58755篇 |
神经病学 | 241139篇 |
特种医学 | 115863篇 |
外国民族医学 | 1042篇 |
外科学 | 438829篇 |
综合类 | 72474篇 |
现状与发展 | 3篇 |
一般理论 | 1168篇 |
预防医学 | 231969篇 |
眼科学 | 69294篇 |
药学 | 215596篇 |
4篇 | |
中国医学 | 5258篇 |
肿瘤学 | 148324篇 |
出版年
2018年 | 28608篇 |
2016年 | 24529篇 |
2015年 | 27871篇 |
2014年 | 40226篇 |
2013年 | 61430篇 |
2012年 | 82698篇 |
2011年 | 87194篇 |
2010年 | 51330篇 |
2009年 | 49067篇 |
2008年 | 82751篇 |
2007年 | 88633篇 |
2006年 | 89241篇 |
2005年 | 87110篇 |
2004年 | 84307篇 |
2003年 | 81329篇 |
2002年 | 79958篇 |
2001年 | 129802篇 |
2000年 | 134126篇 |
1999年 | 113077篇 |
1998年 | 31421篇 |
1997年 | 28380篇 |
1996年 | 27982篇 |
1995年 | 28925篇 |
1994年 | 27269篇 |
1993年 | 25400篇 |
1992年 | 92860篇 |
1991年 | 89756篇 |
1990年 | 86845篇 |
1989年 | 83655篇 |
1988年 | 77934篇 |
1987年 | 76962篇 |
1986年 | 72817篇 |
1985年 | 69904篇 |
1984年 | 53344篇 |
1983年 | 45575篇 |
1982年 | 28123篇 |
1981年 | 25112篇 |
1980年 | 23630篇 |
1979年 | 51162篇 |
1978年 | 36218篇 |
1977年 | 30462篇 |
1976年 | 28494篇 |
1975年 | 30235篇 |
1974年 | 37447篇 |
1973年 | 35819篇 |
1972年 | 33608篇 |
1971年 | 31052篇 |
1970年 | 29355篇 |
1969年 | 27612篇 |
1968年 | 25121篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Hallet Julie Look Hong Nicole J. Zuk Victoria Davis Laura E. Gupta Vaibhav Earle Craig C. Mittmann Nicole Coburn Natalie G. 《Gastric cancer》2020,23(3):373-381
Gastric Cancer - Esophagogastric cancer (EGC) is one of the deadliest and costliest malignancies to treat. Care by high-volume providers can provide better outcomes for patients with EGC. Cost... 相似文献
102.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
103.
Yi Su Jean W. Woo Timothy C.Y. Kwok 《Journal of the American Medical Directors Association》2019,20(1):83-89
Objectives
To examine the potential added value of a simple 5-item questionnaire for sarcopenia screening (SARC-F) to the Fracture Risk Assessment Tool (FRAX) for hip fracture risk prediction, in order to identify at-risk older adults for screening with dual-energy x-ray absorptiometry (DXA).Design
A prospective cohort study.Setting and participants
Two thousand Chinese men and 2000 Chinese women aged 65 years or older were recruited from local communities and were prospectively followed up for about 10 years.Measures
Areal bone mineral density (BMD) of hip and lumbar spine were measured by DXA at baseline. Ten-year FRAX probability of hip fracture was calculated using the baseline risk factors. Information from the baseline questionnaire was extracted to calculate a modified SARC-F score. The independent predictive values of SARC-F and FRAX questionnaire were evaluated using multivariate survival analysis. The added predictive values of SARC-F to FRAX for pre-DXA screening were examined.Results
During the follow-up, 63 (3.2%) men and 69 (3.5%) women had at least 1 incident hip fracture. SARC-F had an independent value of FRAX for hip fracture risk prediction, with an adjusted hazard ratio [95% confidence interval (CI)] of 1.24 (1.02, 1.52) and 1.15 (0.99, 1.13) in men and women, respectively. Compared with using FRAX, using SARC-F in conjunction with FRAX made the sensitivity for prediction rise from 58.7% to 76.2% in men and from 69.6% to 78.3% in women, with a nondecreased area under receiver operating characteristic curve of 0.67. Prescreening using FRAX in conjunction with SARC-F could save more than half of the DXA assessment than with no prescreening.Conclusions/Implications
SARC-F is associated with a modest increase in hip fracture risk, especially in men. Conjoint evaluation for sarcopenia in addition to FRAX screening may help identify older adults at higher risk of hip fracture for more intensive screening and/or preventive interventions. 相似文献104.
105.
106.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
107.
108.
109.
Clinical and Translational Oncology - Breast cancer with positive hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) is a special subgroup with different clinical features... 相似文献
110.